Ondansetron - Teva p / o 8mg tablets, No. 10

Prevention of nausea and vomiting during anticancer chemotherapy or radiation therapy; prevention and treatment of nausea and vomiting in the postoperative period.

The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

Individual, depending on the indications and treatment regimen.

Film-coated tablets 1 tab.

Active ingredient: ondansetron - 8 mg

I trimester of pregnancy, hypersensitivity to ondansetron.

Trade name: Ondansetron-Teva

Composition:

Film-coated tablets 1 tab.

Active ingredient: ondansetron - 8 mg

Clinical and pharmacological group: Centrally acting antiemetic drug that blocks serotonin receptors

Pharmaco-therapeutic group: Antiemetic - serotonin receptor antagonist

pharmachologic effect

Antiemetic. Effectively prevents and eliminates nausea and vomiting that occur during anticancer chemotherapy or radiation therapy, as well as in the postoperative period. The mechanism of action is due to the ability of ondansetron to selectively block serotonin 5-HT3 receptors. It is believed that stimulation of afferent fibers of the vagus nerve with serotonin released from enterochromaffin cells of the gastrointestinal mucosa plays an important role in the occurrence of nausea and vomiting during antitumor therapy. By blocking 5-HT3 receptors, ondansetron prevents the onset of the gag reflex. In addition, ondansetron inhibits the central links of the gag reflex by blocking 5-HT3 receptors in the floor of the IV ventricle (area postrema).

Pharmacokinetics

After oral administration, ondansetron is well absorbed from the gastrointestinal tract. Undergoes a 'first pass' effect through the liver. Protein binding is high (70-76%). Biotransformed in the liver, mainly by hydroxylation. Average T1 / 2 in adult patients is about 4 hours. In case of impaired liver function, an increase in T1 / 2 is noted.

Indications

Prevention of nausea and vomiting during anticancer chemotherapy or radiation therapy; prevention and treatment of nausea and vomiting in the postoperative period.

Dosage regimen

The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

Individual, depending on the indications and treatment regimen.

Side effect

From the side of the central nervous system: headaches; rarely - transient visual impairment and dizziness (with rapid intravenous injection), involuntary movements.

From the side of the cardiovascular system: rarely - chest pain, arrhythmias, bradycardia, arterial hypotension.

From the digestive system: constipation, diarrhea, abdominal pain, transient increase in serum transaminase levels.

Allergic reactions: rarely - bronchospasm, angioedema, urticaria; in some cases - anaphylactic reactions.

Others: feeling of warmth and rush of blood to the head and epigastric region.

Contraindications for use

I trimester of pregnancy, hypersensitivity to ondansetron.

Application during pregnancy and lactation

Ondansetron is contraindicated for use in the first trimester of pregnancy. If necessary, use during lactation should stop breastfeeding.

Application for violations of liver function

When used in patients with moderate and severe hepatic dysfunction, it is not recommended to exceed the dose of 8 mg / day.

special instructions

When used in patients with moderate and severe hepatic dysfunction, it is not recommended to exceed the dose of 8 mg / day.

Ondansetron is used with caution during abdominal surgery, because its use can mask progressive intestinal obstruction.

Drug interactions

Due to the fact that ondansetron is metabolized in the liver by isoenzymes of the cytochrome P450 system, with simultaneous use with drugs that are inducers or inhibitors of this enzyme system, changes in clearance and T1 / 2 of ondansetron are possible.

Storage conditions:

Store at a temperature not exceeding 30 ? C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of dispensing from pharmacies:

On prescription